Showing 3661-3670 of 5975 results for "".
- Survey: Mixed Sentiments for AI in Dermatologyhttps://practicaldermatology.com/news/ai-dermatology-survey-reveals-mixed-sentiments/2467817/A national survey of U.S. dermatologists reveals both enthusiasm and concern about the potential integration of artificial intelligence chatbots (AIC) into dermatological practice. The study, published in the Journal of Drugs in Dermatology, evaluated results from an online cross-sectiona
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- New Plasma Proteins Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/new-plasma-proteins-linked-atopic-dermatitis-risk/2467771/New research has identified eight plasma proteins associated with atopic dermatitis (AD), potentially opening new avenues for treatment. Publishing in the Archives of Dermatological Research, the study authors used summary-data-based Mendelian Randomization (SMR) and evaluated dat
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p
- Annual Science of Skin Event Highlights Empowering Conversations About Chronic Diseaseshttps://practicaldermatology.com/news/annual-science-skin-event-highlights-empowering-conversations-about-chronic-diseases/2467751/Empowering conversations around chronic skin diseases is something AbbVie aims to normalize. The fourth annual Science of Skin event featured a panel of experts and patients who shared insights on managing chronic skin conditions and improving quality of life, and Practical Dermatology was there.
- GUIDE: Guselkumab Dosing Every 16 Weeks Maintains Psoriasis Controlhttps://practicaldermatology.com/news/guide-guselkumab-dosing-every-16-weeks-maintains-psoriasis-control/2467730/Results from the GUIDE clinical trial showed that an extended dosing interval of guselkumab was effective for the treatment of moderate-to-sever plaque psoriasis. "Psoriasis is a chronic, systemic immune-mediated disease, predominately characterized by skin plaques, "the researchers wrote
- Tildrakizumab Shows Efficacy in Plaque Psoriasishttps://practicaldermatology.com/news/tildrakizumab-shows-significant-efficacy-plaque-psoriasis/2467713/Tildrakizumab was associated with improvements in disease severity in patients with moderate-to-severe plaque psoriasis, according to results from a new study in the Journal of Drugs in Dermatology. Researchers for the phase 4, multicenter, uncontrolled, open-label trial enrolle
- New Algorithm Helps Detect Aggressive Basal Cell Carcinoma for Optimal Treatmenthttps://practicaldermatology.com/news/new-algorithm-helps-detect-aggressive-basal-cell-carcinoma-optimal-treatment/2467648/An algorithm can help healthcare professionals recognize which patients have a highly aggressive form of basal cell carcinoma (BCC) of the face. These are the findings of a study conducted at the University of Gothenburg. If more BCCs are correctly identified as high-risk, the patients can direct
- European Committee Recommends Approval of Delgocitinib for CHEhttps://practicaldermatology.com/news/european-committee-recommends-approval-delgocitinib-che/2467631/The European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) has “adopted a positive opinion that recommends the approval” of delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequ
- Nemolizumab Meets Key Endpoints in ARCADIA Studieshttps://practicaldermatology.com/news/nemolizumab-meets-key-endpoints-arcadia-studies/2467533/Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, showed efficacy for the treatment of atopic dermatitis, particularly pruritus and sleep disturbance, according to an announcement from Galderma. The full results of the phase III ARCADIA 1 and 2 trials for nemolizumab were pu